Aerie Pharmaceuticals Inc. (NASDAQ:AERI) major shareholder Foresite Capital Fund Ii, L.P. sold 50,000 shares of the stock in a transaction on Thursday, October 6th. The shares were sold at an average price of $40.34, for a total value of $2,017,000.00. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Foresite Capital Fund Ii, L.P. also recently made the following trade(s):

  • On Friday, July 22nd, Foresite Capital Fund Ii, L.P. purchased 250,000 shares of Aerie Pharmaceuticals stock. The stock was bought at an average cost of $17.50 per share, with a total value of $4,375,000.00.

Shares of Aerie Pharmaceuticals Inc. (NASDAQ:AERI) opened at 40.49 on Friday. Aerie Pharmaceuticals Inc. has a 52-week low of $10.82 and a 52-week high of $41.72. The stock’s market cap is $1.13 billion. The firm’s 50-day moving average price is $28.57 and its 200-day moving average price is $19.49.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its earnings results on Wednesday, August 3rd. The company reported ($0.72) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.02. Equities analysts predict that Aerie Pharmaceuticals Inc. will post ($2.81) EPS for the current year.

A number of research firms have recently commented on AERI. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $50.00 price target on shares of Aerie Pharmaceuticals in a report on Saturday. Zacks Investment Research raised Aerie Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $20.00 price target for the company in a report on Monday, July 4th. Stifel Nicolaus raised their price target on Aerie Pharmaceuticals from $40.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, September 15th. Brean Capital reaffirmed a “buy” rating and issued a $63.00 price target on shares of Aerie Pharmaceuticals in a report on Thursday. Finally, Royal Bank Of Canada raised their price target on Aerie Pharmaceuticals from $51.00 to $55.00 and gave the stock an “outperform” rating in a report on Thursday, September 15th. One equities research analyst has rated the stock with a sell rating and nine have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $51.40.

A number of large investors have recently made changes to their positions in AERI. First Mercantile Trust Co. bought a new stake in shares of Aerie Pharmaceuticals during the third quarter worth $161,000. Barclays PLC raised its stake in shares of Aerie Pharmaceuticals by 3.4% in the second quarter. Barclays PLC now owns 6,015 shares of the company’s stock worth $106,000 after buying an additional 200 shares in the last quarter. BlackRock Advisors LLC raised its stake in shares of Aerie Pharmaceuticals by 15.0% in the second quarter. BlackRock Advisors LLC now owns 12,310 shares of the company’s stock worth $217,000 after buying an additional 1,608 shares in the last quarter. GSA Capital Partners LLP bought a new stake in shares of Aerie Pharmaceuticals during the second quarter worth $219,000. Finally, American International Group Inc. raised its stake in shares of Aerie Pharmaceuticals by 8.5% in the second quarter. American International Group Inc. now owns 13,864 shares of the company’s stock worth $244,000 after buying an additional 1,082 shares in the last quarter. Institutional investors and hedge funds own 95.22% of the company’s stock.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.

5 Day Chart for NASDAQ:AERI

Receive News & Stock Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.